COAPT试验不合格的功能性二尖瓣反流患者经导管缘对缘修复的结局
基于TVT注册研究2013年至2020年6675例因功能性二尖瓣反流接受MTEER的患者,44.3%不符合COAPT试验标准。不合格组技术成功率更低、院内并发症更多,30天健康状况改善与合格组相似,但1年死亡或心衰住院风险更高(HR 1.73)。
要点
- 近半数因FMR接受MTEER的患者不符合COAPT试验标准。
- 不合格组技术成功率86.9%低于合格组92.6%,院内并发症11.8%高于5.7%。
- 不合格组1年死亡或心衰住院风险更高(HR 1.73,95%CI 1.57-1.91)。
核心结论
- 在TVT注册研究中,因FMR接受MTEER的患者近一半不符合COAPT试验标准,其1年死亡或心衰住院风险显著高于合格患者。
研究设计与样本
- 回顾性注册研究,纳入2013年1月1日至2020年4月30日TVT注册研究中因FMR接受MTEER的6675例患者,按COAPT试验标准分为合格组3721例和不合格组2954例,随访1年。
主要发现
- 不合格组技术成功率86.9%,合格组92.6%(P<0.001)。
- 不合格组院内并发症发生率11.8%,合格组5.7%(P<0.001)。
- 30天健康状况临床有意义改善率在不合格组为78.9%,合格组为77.0%。
- 不合格组1年死亡或心衰住院风险更高(HR 1.73;95%CI 1.57-1.91;P<0.001)。
关键数值与推荐
- COAPT试验不合格标准包括:心源性休克、正性肌力药物支持、左心室射血分数<20%、左心室收缩末期内径>7 cm、家庭氧疗或重度三尖瓣反流。
临床怎么用
- 对于不符合COAPT标准的FMR患者,MTEER仍可改善30天健康状况,但需告知1年死亡或心衰住院风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mitral valve transcatheter edge-to-edge repair (MTEER) was approved in the United States for treatment of functional mitral regurgitation (FMR) based on results from the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial. OBJECTIVES: The authors sought to analyze outcomes of MTEER in FMR patients who would have been excluded from COAPT. METHODS: MTEER procedures performed for FMR in the TVT (Transcatheter Valve Therapy) Registry between January 1, 2013, and April 30, 2020, were categorized as "trial-ineligible" if any of the following were present: cardiogenic shock, inotropic support, left ventricular ejection fraction <20%, left ventricular end-systolic dimension >7 cm, home oxygen use, or severe tricuspid regurgitation. Trial-ineligible and trial-eligible groups were compared through 1 year using multivariable models. The primary endpoint was 1-year death or heart failure hospitalization (HFH). RESULTS: Of 6,675 patients who underwent MTEER for FMR, 3,721 (55.7%) were trial-eligible and 2,954 (44.3%) were trial-ineligible. Trial-ineligible patients had lower rates of technical procedural success (86.9% vs 92.6%; P < 0.001) and more frequent in-hospital complications (11.8% vs 5.7%; P < 0.001) compared with trial-eligible patients. A clinically meaningful improvement in health status at 30 days was observed in 78.9% and 77.0% of patients in the trial-ineligible and trial-eligible groups, respectively. There was a higher risk of 1-year death or HFH (HR: 1.73; 95% CI: 1.57-1.91; P < 0.001) in trial-ineligible patients. CONCLUSIONS: Among patients who underwent MTEER for FMR in the TVT Registry, nearly one-half would have been ineligible for the COAPT trial. Health status improvement at 30 days was similar in COAPT-ineligible and COAPT-eligible patients, but trial-ineligible patients had higher 1-year rates of death or HFH.
引用
- Chhatriwalla, Cohen, Vemulapalli, et al. Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients With Functional Mitral Regurgitation. J Am Coll Cardiol. 2024. PMID: 38267110. doi:10.1016/j.jacc.2023.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。